Short-term celecoxib (celebrex) adjuvant therapy: a clinical trial study on COVID-19 patients.

Habib GhaznaviZahra MohammadghasemipourMilad ShirvalilooMohammad Kazem MomeniMalihe MetanatFarzaneh GorganiFatemeh AbedipourMahdi MohammadiMajid SartipiAli Reza Salimi KhorashadOmolbanin ShahrakiMohadese AtaeeRoghayeh SheervalilouSaman Sargazi

Published in: Inflammopharmacology (2022)

Celecoxib is a relatively safe, inexpensive, and widely available drug with non-steroidal anti-inflammatory properties. The therapeutic efficacy of celecoxib depends on the administrated dose. Celecoxib might improve disease-free survival in patients with COVID-19.

Keyphrases

free survival
clinical trial
anti inflammatory
sars cov
emergency department
study protocol
randomized controlled trial